HMGB2 and ovarian carcinoma: To examine the relevance of the HMGB2-TOP1cc-cGAS pathway in immune checkpoint blockade treatment, we utilized an immune competent syngeneic ovarian cancer ID8-Defb29/Vegf-a mouse model21,22.